U.S. Healthtech Stock News

CSX expanded its Select Site initiative by awarding its designation to 21 new rail served properties across 10 states. Owens Corning announced a large manufacturing investment at a CSX Silver Select Site in Alabama, tied to about 100 new skilled jobs. This development reflects fresh industrial interest in CSX served locations, beyond recent discussions focused on valuation, margin outlook, and service metrics for NasdaqGS:CSX. For investors tracking NasdaqGS:CSX, this move adds a fresh...

In March 2026, Aldeyra Therapeutics reported that the FDA issued a Complete Response Letter for its reproxalap dry eye disease NDA, citing insufficient and inconsistent evidence of efficacy despite no safety or manufacturing concerns. An important nuance is that the FDA did not request new trials, instead urging Aldeyra to clarify why certain studies failed and where reproxalap might work best. We’ll now examine how the FDA’s efficacy concerns and lack of requested new trials reshape...

Johnson Controls International (NYSE:JCI) has agreed to sell its residential HVAC business to Bosch, reallocating focus toward data center and service solutions. The company is expanding offerings for AI oriented data centers, including a partnership with NVIDIA to support advanced cooling needs. Management has highlighted backlog growth as evidence of strong demand for these focus areas. For investors tracking NYSE:JCI, this shift comes with the stock at $132.56 and a 1 year return of...

Traeger, Inc. has already implemented a 1-for-50 reverse stock split on March 18, 2026, following stockholder approval earlier in the month to address a New York Stock Exchange notice that its shares had traded below US$1.00 for 30 consecutive trading days. This reverse split, combined with recent weak 2025 results and ongoing losses, highlights how Traeger is using financial tools rather than operational improvements alone to preserve its exchange listing. Next, we'll explore how Traeger's...

Before deciding whether Brightstar Lottery looks attractively priced, it helps to pin down what you are really getting for each dollar of its current US$12.74 share price. The stock has seen a 0.2% slip over the last week, a 5.3% decline over the last month, and is down 16.7% year to date, with a 4.7% decline over the last 12 months and a 32.7% decline over 3 years, even though the 5 year return sits at 7.0%. These mixed returns frame the key question of whether recent weakness reflects...

Comtech Telecommunications (CMTL) has just posted Q2 2026 results that keep the focus squarely on profitability, with Q1 2026 revenue of US$111.0 million, a basic EPS loss of US$0.67, and net income loss of US$19.8 million. Over recent quarters the company has seen revenue move from US$115.8 million and an EPS loss of US$52.93 in Q1 2025 to US$130.4 million and an EPS loss of US$0.39 in Q4 2025, with net income losses shifting from US$155.9 million to US$11.6 million across the same period...

Embassy Bancorp (EMYB) has posted a clean set of Q3 2025 numbers, with total revenue of US$11.7 million and basic EPS of US$0.50, against a 12 month backdrop where revenue on a trailing basis moved from US$39.8 million to US$44.0 million and EPS from US$1.37 to US$1.68. The latest quarter sits within a year where earnings grew 21.3% versus the longer term trend and sets the stage for investors to focus on how a 29.1% net margin and a 2.58% net interest margin shape the quality and resilience...

Black Diamond Therapeutics (BDTX) just posted a sharp swing into profit for FY 2025, with first half revenue of US$70 million translating to basic EPS of US$0.81, compared with losses in both halves of FY 2024. Over the past year, the company has seen revenue move from US$0 to US$70 million while basic EPS has shifted from losses of US$0.71 and US$0.56 in FY 2024 to a trailing 12 month figure of US$0.25. This sets up a results season where investors will focus squarely on how durable these...

Q3 2026 snapshot: Value Line (VALU) leans on margins as earnings trends soften Value Line (VALU) has just reported its Q3 2026 results, with recent quarters showing revenue around US$8.6 million and basic EPS between US$0.42 and US$0.69, while trailing twelve month EPS sits a little above US$2.25. Over the last six reported quarters, revenue has ranged from US$8.39 million to US$8.97 million and basic EPS has moved between US$0.42 and US$0.69, setting up a picture where high profitability...

Coya Therapeutics (COYA) has released its FY 2025 results, reporting fourth quarter revenue of US$4.0 million and a basic EPS loss of US$0.34, alongside trailing twelve month revenue of US$7.9 million and a basic EPS loss of US$1.27. The company’s revenue increased from US$0.00 million in the third quarter of 2024 to US$3.6 million in the third quarter of 2025, while quarterly basic EPS has ranged from a loss of US$0.44 in the first quarter of 2025 to a loss of US$0.13 in the third quarter of...

Zomedica (OTCPK:ZOMD.F) has reported its FY 2025 third quarter with total revenue of US$8.1 million and a basic EPS loss of US$0.006, alongside a net loss of US$6.1 million. Over recent quarters, revenue has moved from US$6.1 million in Q2 2024 to US$6.5 million in Q1 2025 and US$8.1 million in Q3 2025, while quarterly net losses have ranged from US$6.1 million to US$63.8 million and trailing twelve month revenue has reached US$29.5 million against a trailing net loss of US$84.5 million. For...

Orange County Bancorp (OBT) has just wrapped up FY 2025 with fourth quarter total revenue of US$31.5 million, basic EPS of US$0.93 and net income of US$12.4 million. This sets the tone for how investors will read the full year against recent momentum in the share price around US$31.40. The company has seen revenue move from US$27.4 million and EPS of US$0.63 in Q4 2024 to US$31.5 million and EPS of US$0.93 in Q4 2025. Trailing twelve month figures sit at US$119.5 million of revenue and EPS of...

Primis Financial's FY 2025 Earnings Snapshot Primis Financial (FRST) closed FY 2025 with fourth quarter revenue of US$78.4 million and basic EPS of US$1.20, while trailing twelve month revenue reached US$211.3 million and EPS came in at US$2.49. Over recent periods, revenue has moved from US$5.8 million in Q4 2024 to US$78.4 million in Q4 2025, and basic EPS has shifted from a loss of US$0.94 per share in Q4 2024 to EPS of US$1.20, putting margins and profitability under closer scrutiny for...

Bicycle Therapeutics (BCYC) has just posted its FY 2025 third quarter numbers, with revenue of about US$11.7 million and a basic EPS loss of US$0.85. Trailing twelve month figures show revenue of roughly US$28.3 million and a basic EPS loss of US$3.62. Over recent quarters, revenue has ranged from US$2.9 million to US$11.7 million, while quarterly basic EPS losses have moved between US$0.74 and US$1.14. This gives investors a clearer sense of a business that appears to be in investment mode...

Bakkt (BKKT) just posted its FY 2025 results with third quarter revenue of US$402.2 million and a basic EPS loss of US$1.02, while trailing twelve month revenue sat at US$3.9 billion against a basic EPS loss of US$5.06. Over recent periods, revenue has ranged from US$214.5 million in Q4 2023 to US$1.8 billion in Q4 2024 and US$1.1 billion in Q1 2025, with EPS swinging between a loss of US$7.25 in Q4 2023 and a profit of US$1.18 in Q1 2025. This gives investors a mixed picture on earnings...

American Vanguard (AVD) opened FY 2025 with mixed results, reporting Q3 revenue of US$119.3 million and a basic EPS loss of US$0.43, while on a trailing twelve month basis revenue stood at US$530.1 million alongside a basic EPS loss of US$3.96. The company has seen quarterly revenue move between US$115.8 million and US$165.6 million over the past six reported quarters, with basic EPS losses ranging from US$0.03 to US$3.21. This highlights pressure on profitability even as the top line remains...

HF Foods Group (HFFG) has just posted its FY 2025 third quarter numbers, with revenue at US$307 million and a basic EPS loss of US$0.02, while on a trailing 12 month basis revenue sits at about US$1.23 billion and basic EPS at a loss of US$0.86. The company has seen quarterly revenue move from US$302 million in Q2 FY 2024 to US$307 million in Q3 FY 2025, with basic EPS shifting across that period from roughly breakeven at US$0.00 in Q2 FY 2024 to a loss of US$0.02 in the latest quarter...

CytomX Therapeutics earnings and Varseta-M data come into focus CytomX Therapeutics (CTMX) is back on radar after reporting full year 2025 results alongside early Phase 1 expansion data for its EpCAM-targeting ADC, Varseta-M, in late-line metastatic colorectal cancer. See our latest analysis for CytomX Therapeutics. The recent Varseta-M data, full year 2025 results and a new shelf registration plus follow-on equity filing have coincided with sharp share price momentum, with a 1 day share...

Iron Mountain (NYSE:IRM) has agreed to acquire ACT Logistics in Australia as part of its global expansion. The company continues to grow its data center segment, adding to its traditional records management operations. Iron Mountain recently raised its dividend by 10%, highlighting its focus on shareholder returns. Iron Mountain, best known for records storage and information management, is in the middle of a meaningful shift in where its business is growing. The ACT Logistics deal broadens...

Invesco, NYSE:IVZ, has introduced an employee benefit that supports new U.S. government "Trump Accounts" under Section 530A child savings accounts. The company plans to match the initial government contribution for eligible children of its employees, adding a private employer layer to the federal program. This move links Invesco's employee benefits directly to a current policy initiative focused on long term child savings. For investors tracking NYSE:IVZ, this new benefit sits alongside a...

Stock performance context for CorMedix Without a specific news catalyst driving fresh headlines, CorMedix (CRMD) continues to draw attention as investors weigh its recent share performance in relation to its role in developing therapies for life threatening conditions. The stock last closed at US$6.54, with returns showing mixed momentum. It recorded a 1.4% gain over the past day, alongside a slight decline over the past week. See our latest analysis for CorMedix. Recent trading tells a mixed...

Silvaco Group (SVCO) surprised the market with quarterly results that came in ahead of expectations, along with revenue guidance above earlier forecasts and cost cuts tracking better than management initially outlined. See our latest analysis for Silvaco Group. Silvaco Group’s recent earnings beat and upbeat guidance have been met with sharp share price momentum, with a 7 day share price return of 53.5% and a year to date share price return of 22%, even though the 1 year total shareholder...

Cytokinetics (NasdaqGS:CYTK) presented new clinical data on MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy at a major cardiology conference. The updates covered exercise capacity outcomes, effectiveness across patients with and without hypertension, and safety during treatment interruption and restart. The new analyses expand the clinical profile of MYQORZO, a recently approved oHCM therapy, and add detail on how the drug performs in real treatment scenarios. Cytokinetics...

Lifecore Biomedical (LFCR) just posted its FY 2025 fourth quarter numbers, with revenue of US$36.4 million and a basic EPS loss of US$0.06. This sets the tone for a year where the trailing twelve months show revenue at about US$129.5 million and a basic EPS loss of US$0.92. Over recent quarters, revenue has moved from US$24.7 million in Q1 FY 2025 to US$31.1 million in Q3 and then US$36.4 million in Q4. Quarterly basic EPS losses ranged from US$0.53 in Q1 to US$0.29 in Q3 and US$0.06 in Q4,...